Hibiscus, an adaptive, randomized, placebo-controlled, double-blind, multi-centre study of oral FT-4202, a pyruvate kinase activator in patients with sickle cell disease
Conferences
Wood, K; Geib, J; Wu, E; Berlin, J; Webster, I; Ataga, K; Howard, J; Estepp, J; Telen, M; Brevard, J
Published in: BRITISH JOURNAL OF HAEMATOLOGY
April 2021
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
BRITISH JOURNAL OF HAEMATOLOGY
EISSN
1365-2141
ISSN
0007-1048
Publication Date
April 2021
Volume
193
Start / End Page
31 / 32
Related Subject Headings
- Immunology
- 3201 Cardiovascular medicine and haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Wood, K., Geib, J., Wu, E., Berlin, J., Webster, I., Ataga, K., … Brevard, J. (2021). Hibiscus, an adaptive, randomized, placebo-controlled, double-blind, multi-centre study of oral FT-4202, a pyruvate kinase activator in patients with sickle cell disease. In BRITISH JOURNAL OF HAEMATOLOGY (Vol. 193, pp. 31–32).
Wood, Kenneth, James Geib, Eric Wu, Jason Berlin, Irena Webster, Kenneth Ataga, Jo Howard, Jeremie Estepp, Marilyn Telen, and Julie Brevard. “Hibiscus, an adaptive, randomized, placebo-controlled, double-blind, multi-centre study of oral FT-4202, a pyruvate kinase activator in patients with sickle cell disease.” In BRITISH JOURNAL OF HAEMATOLOGY, 193:31–32, 2021.
Wood K, Geib J, Wu E, Berlin J, Webster I, Ataga K, et al. Hibiscus, an adaptive, randomized, placebo-controlled, double-blind, multi-centre study of oral FT-4202, a pyruvate kinase activator in patients with sickle cell disease. In: BRITISH JOURNAL OF HAEMATOLOGY. 2021. p. 31–2.
Wood, Kenneth, et al. “Hibiscus, an adaptive, randomized, placebo-controlled, double-blind, multi-centre study of oral FT-4202, a pyruvate kinase activator in patients with sickle cell disease.” BRITISH JOURNAL OF HAEMATOLOGY, vol. 193, 2021, pp. 31–32.
Wood K, Geib J, Wu E, Berlin J, Webster I, Ataga K, Howard J, Estepp J, Telen M, Brevard J. Hibiscus, an adaptive, randomized, placebo-controlled, double-blind, multi-centre study of oral FT-4202, a pyruvate kinase activator in patients with sickle cell disease. BRITISH JOURNAL OF HAEMATOLOGY. 2021. p. 31–32.
Published In
BRITISH JOURNAL OF HAEMATOLOGY
EISSN
1365-2141
ISSN
0007-1048
Publication Date
April 2021
Volume
193
Start / End Page
31 / 32
Related Subject Headings
- Immunology
- 3201 Cardiovascular medicine and haematology